Blood pressure lowering effect of combination therapy of angiotensin receptor blocker (ARB) and Ca antagonist in patients with high risk hypertension

Blood pressure lowering effect of combination therapy of angiotensin receptor blocker (ARB) and Ca antagonist in patients with high risk hypertension - Therapeutic efficacy of combination therapy of angiotensin receptor blocker (ARB) and Ca antagonist to patients with high risk hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002207

Enrollment

Registered

2009-07-22

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Combination of olmesartan medoxomil 20mg/day and azelnidipine 16mg/day Combination of valsartan 80mg/day and amlodipine besilate 5mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive patients categolized into high risk group

Exclusion criteria

Exclusion criteria: 1. Patients with hypersensitive history to olmesartan medoxomil, azelnidipine, valsartan and amlodipine besilate 2. Pregnant women or women who have possibility of pregnancy 3. Patients administrated with azole antifungal drug or protease inhibitor

Design outcomes

Primary

Measure	Time frame
Blood lowering effect and percentage of the attainment of therapeutic goal three and six months after treatment	—

Secondary

Measure	Time frame
Chenges of various biomarker six months after treatment	—

Countries

Japan

Contacts

Public ContactTakashi Iwase

Institute of Health Biosciences, The University of Tokushima Graduate School Department of Cardiovascular Medicine

tiwase@clin.med.tokushima-u.ac.jp088-633-7851

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026